Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.
Hernández-Rodríguez J, Durán-Sanclemente J, Prieto-González S, Araújo O, Hospital-Vidal T, Casanovas G, Sapena V, Blanco JL, López-Soto A; FRAGILE-COLCOVID19 Study Group. Hernández-Rodríguez J, et al. Among authors: blanco jl. Clin Drug Investig. 2022 Nov;42(11):949-964. doi: 10.1007/s40261-022-01201-2. Epub 2022 Sep 29. Clin Drug Investig. 2022. PMID: 36173596 Free PMC article. Clinical Trial.
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
Martínez-Serra A, De Lazzari E, Berrocal L, Foncillas A, De La Mora L, Inciarte A, Chivite I, González-Cordón A, Martínez-Rebollar M, Torres B, Laguno M, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Martínez-Serra A, et al. Among authors: blanco jl. J Antimicrob Chemother. 2023 Aug 2;78(8):1955-1962. doi: 10.1093/jac/dkad189. J Antimicrob Chemother. 2023. PMID: 37311224
Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient.
Ambrosioni J, Coll S, Manzardo C, Nicolás D, Agüero F, Blanco JL, Tuset M, Brunet M, Gatell JM, Miró JM. Ambrosioni J, et al. Among authors: blanco jl. J Antimicrob Chemother. 2016 Apr;71(4):1125-7. doi: 10.1093/jac/dkv449. Epub 2016 Jan 10. J Antimicrob Chemother. 2016. PMID: 26755498 No abstract available.
Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome.
Torres B, Alcubilla P, González-Cordón A, Inciarte A, Chumbita M, Cardozo C, Meira F, Giménez M, de Hollanda A, Soriano A; COVID19 Hospital Clínic Infectious Diseases Research Group. Torres B, et al. Int J Infect Dis. 2021 Mar;104:164-168. doi: 10.1016/j.ijid.2020.11.207. Epub 2020 Dec 2. Int J Infect Dis. 2021. PMID: 33278624 Free PMC article.
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Leal L, Couto E, Sánchez-Palomino S, Climent N, Fernández I, Miralles L, Romero Y, González T, Maleno MJ, Paño B, Pich J, Nicolau C, Gatell JM, Plana M, García F; DCV3-RISVAC04 Study Group. Leal L, et al. Front Immunol. 2021 Nov 11;12:767370. doi: 10.3389/fimmu.2021.767370. eCollection 2021. Front Immunol. 2021. PMID: 34858423 Free PMC article. Clinical Trial.
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martínez-Rebollar M, et al. Among authors: blanco jl. Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef. Ther Drug Monit. 2013. PMID: 23851911
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).
Inciarte A, Ugarte A, Martínez-Rebollar M, Torres B, Fernández E, Berrocal L, Laguno M, De la Mora L, De Lazzari E, Callau P, Chivite I, González-Cordón A, Solbes E, Rico V, Barrero L, Blanco JL, Martínez E, Ambrosioni J, Mallolas J; DORAVIPEP Study Group. Inciarte A, et al. Among authors: blanco jl. Open Forum Infect Dis. 2023 Jul 19;10(8):ofad374. doi: 10.1093/ofid/ofad374. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539061 Free PMC article.
Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M, Martínez-Rebollar M, Casanova M, de Lazzari E, González-Cordón A, Torres B, Inciarte A, Mora L, Ugarte A, Ambrosioni J, Blanco JL, Martínez E, Mallolas J. Laguno M, et al. Among authors: blanco jl. Clin Microbiol Infect. 2022 Apr;28(4):610.e1-610.e7. doi: 10.1016/j.cmi.2021.08.019. Epub 2021 Aug 28. Clin Microbiol Infect. 2022. PMID: 34464735 Free article.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
337 results